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Abstract
Background
Gastric cancer with undifferentiated histology has different clinicopathologic characteristics
compared to differentiated type gastric cancer. We aimed to compare the risk of synchro-
nous or metachronous tumors after curative resection of early gastric cancer (EGC) via
endoscopic submucosal dissection (ESD), according to the histologic differentiation of the
primary lesion.
Methods
Clinicopathological data of patients with initial-onset EGC curatively resected via ESD
between January 2007 and November 2014 in a single institution were reviewed. We ana-
lyzed the incidence of synchronous or metachronous tumors after ESD with special refer-
ence to the differentiation status of the primary lesion.
Results
Of 1,560 patients with EGC who underwent curative resection via ESD, 1,447 had differenti-
ated type cancers, and 113 had undifferentiated type cancers. The cumulative incidence of
metachronous or synchronous tumor after ESD was higher in the differentiated cancer
group than in the undifferentiated cancer group (P = 0.008). Incidence of metachronous or
synchronous tumor was 4.8% and 1.2% per person-year in the differentiated and undiffer-
entiated cancer groups, respectively. The Cox proportional hazard model revealed that
undifferentiated cancers were associated with a low risk of synchronous or metachronous
tumors after adjusting for confounding variables (hazard ratio [95% confidence interval] =
0.287 [0.090–0.918]).
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Conclusions
The rate of synchronous or metachronous tumors after curative ESD was significantly lower
for undifferentiated cancers compare to differentiated cancers. These findings suggest that
ESD should be actively considered as a possible treatment for undifferentiated type EGCs.
Introduction
Endoscopic submucosal dissection (ESD) is widely used for the treatment of early gastric can-
cer with expanded indications [1–4]. The expanded indications for ESD, which were proposed
by Gotoda et al., consist of four categories based on a combination of multiple tumor character-
istics including tumor differentiation, depth of tumor invasion, tumor size, presence of ulcers,
and presence of lymphovascular invasion [5]. Although the possibility of lymph node metasta-
sis is very low in all four categories [6], Gotoda et al. recommended considering surgery for
undifferentiated cancers because endoscopic en-bloc resection is sometimes difficult in these
cancers [5]. Actually, the curative resection rate is lower for undifferentiated cancers than for
differentiated cancers, even for lesions that clearly fulfill the ESD indications [7]. One of the
main reasons for the low curative resection rate of ESD for undifferentiated cancers is a higher
incomplete resection rate compared to differentiated cancers [1]. Because the margins of undif-
ferentiated early gastric cancers (EGCs) are usually poorly defined, it is difficult to determine
the exact lesion size and assess whether the lesion meets ESD indications [8]. However, many
studies have revealed that ESD produces good long-term oncologic outcomes for undifferenti-
ated cancers if curative resection has been achieved [7,9,10]. Therefore, ESD can be a good
treatment option for selected undifferentiated cancers.
Previously, the clinical and oncologic outcomes after ESD for undifferentiated cancers have
been addressed from the perspective of a non-inferiority design compared to outcomes for dif-
ferentiated cancers. However, we decided to assume that ESD for undifferentiated cancers
might be superior to that for differentiated cancers in terms of the risk of synchronous or meta-
chronous tumors.
The undifferentiated type is more frequent than the differentiated type in theH. pylori-neg-
ative gastric cancers [11]. Considering thatH. pylori infection is a well-known risk factor for
gastric cancer [12], incidence of synchronous or metachronous tumors might differ between
differentiated and undifferentiated type gastric cancers. If the incidence rate of synchronous or
metachronous tumors after ESD for undifferentiated cancers would be significantly lower than
after ESD for differentiated cancers, then the reason for using ESD for undifferentiated cancers
would be strengthened. However, the incidence of synchronous or metachronous tumors after
ESD has not been fully evaluated by considering the histologic differentiation of the primary
gastric cancer. In this study, therefore, we aimed to compare the risk of synchronous or meta-
chronous tumors after curative resection of EGC via ESD, according to the histologic differen-
tiation of the primary lesion.
Methods
Patients
We retrospectively reviewed the clinical data of patients who underwent ESD for initial-onset
gastric cancer between January 2007 and November 2014 at Severance Hospital, Seoul, Korea.
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Patient records/information was anonymized and de-identified prior to analysis. The Institu-
tional Review Board of Severance Hospital approved this study.
Because patients often underwent subsequent surgery after ESD with non-curative resec-
tion, we excluded patients with gastric cancer resected non-curatively via ESD for analyzing
the risk of synchronous or metachronous tumors. The data were obtained from the prospec-
tively established database of patients who underwent ESD at Severance Hospital, Seoul, Korea.
ESD for gastric cancer was performed based on the expanded indication, as previously
described [5]: (a) differentiated intramucosal adenocarcinoma less than 3 cm in diameter with-
out lymphovascular invasion, irrespective of the ulcer findings; (b) differentiated intramucosal
adenocarcinoma without lymphovascular invasion and negative for ulceration, irrespective of
the tumor size; (c) undifferentiated intramucosal cancer less than 2 cm without lymphovascu-
lar invasion and ulcer findings; and (d) differentiated adenocarcinoma less than 3 cm with
minimal submucosal invasion (<500 μm) and without lymphovascular invasion. When a
tumor that fulfilled the expanded indication criteria was removed as a single piece without frag-
mentation and all lateral and vertical margins were tumor-free on histologic examination, it
was considered to have been resected curatively.
Patients were proven to be infected with H. pylori by the following three methods: (a) histo-
logic evidence of H. pylori; (b) a positive rapid urease test campylobacter-like organism; (c) a
positive 13C-urea breath test. H. pylori infection was defined as a positive result from any of the
three tests. In addition, atrophic gastritis and intestinal metaplasia were assessed considering
the endoscopic findings [13–16]. The treatment ofH. pylori was decided according to the phy-
sician’s recommendation and patient’s preference.
ESD technique
All ESD procedures were performed with a standard single-channel endoscope (GIF-Q260J or
GIF-H260Z, Olympus Optical Co. Ltd., Tokyo, Japan). The typical procedure sequence con-
sisted of marking, mucosal incision, and then submucosal dissection with simultaneous hemo-
stasis. The details of each step are described below.
Firstly, lesion was examined via chromoendoscopy using indigo carmine dye spraying.
After making several marking dots circumferentially around the lesion with a needle knife
(KD-10Q-1-A, Olympus Optical Co. Ltd., Tokyo, Japan) or a needle knife papillotome (MTW
Endoscopy, Wesel, Germany), a saline solution containing epinephrine (0.01 mg/mL) mixed
with indigo carmine was injected into the submucosal layer by using a 21-gauge needle in
order to lift the lesion away from the muscle layer. A circumferential incision was made in the
mucosa by using a needle knife and an insulated-tip knife (KD-610L, Olympus Optical Co.
Ltd., Tokyo, Japan). The submucosal layer was dissected directly with various knives until com-
plete removal was achieved. Endoscopic hemostasis was performed with hemoclips or hemo-
static forceps whenever bleeding or exposed vessels were observed.
Histologic evaluation and assessment of resection efficacy
All resected specimens were systematically sectioned at 2 mm intervals, centered on the part of
the lesion closest to the margin and the site of the deepest invasion. Histological assessment
was based on the Vienna classification [17]. Final pathologic diagnosis was made based on the
predominant histology of lesion. Additionally final pathologic diagnoses were classified as gas-
tric cancer with differentiated or undifferentiated histology as Japanese classification [18].
Undifferentiated type included poorly differentiated adenocarcinoma, signet-ring cell carci-
noma, and mucinous adenocarcinoma, while differentiated type included papillary adenocarci-
noma and well- to moderate differentiated adenocarcinoma.
ESD for Undifferentiated Gastric Cancer
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Follow-up
All patients underwent an esophagogastroduodenoscopy (EGD) with biopsy, which was sched-
uled at 3, 6, 12, 18, and 24 months after ESD to check for recurrent tumors. After 24 months,
EGD was performed annually. Tumor recurrences found during follow-up EGD were classified
into two groups: (a) local recurrence, which was defined as adenoma or cancer detected at the
resection site after ESD, (b) adenoma or cancer detected at a gastric site other than the primary
resection area after ESD. The latter was further classified into synchronous and metachronous
tumor according to the time of recurrence. When adenoma or cancer was detected at a gastric
site other than the primary resection area on the follow-up EGD within 12 months after ESD,
it was defined as a synchronous tumor. Adenoma or cancer detected at a site other than the pri-
mary resection area at 12 months or more after ESD was defined as a metachronous tumor.
We analyzed the incidence of recurrence according to the site of recurrence (primary resection
site vs. other than primary resection site) and the differentiation status of the primary lesion.
Statistical analysis
Categorical variables were presented as a sample number with the proportion and were ana-
lyzed with the chi-square test or Fisher exact test. Follow-up duration was presented as a
median with an interquartile range (IQR), and the data were analyzed with the Mann-Whitney
U test. The Kaplan-Meier method and log-rank test were used for the survival analyses. In
addition, P-value of log-rank test among three groups according to the atrophic gastritis and
intestinal metaplasia (IM) was adjusted using the Bonferroni correction. The Cox proportional
hazard model was used to adjust for possible confounding variables for age, sex, H. pylori infec-
tion status, atrophic gastritis or IM, tumor differentiation, tumor location, tumor size, presence
of ulcer, and depth of tumor invasion. The level of significance was set as P< 0.05. All statisti-
cal analyses were performed with the statistical software package SPSS for Windows version
18.0 (SPSS Inc., Chicago, IL).
Results
Baseline patient and lesion characteristics
A total of 2,118 patients with 2,169 lesions underwent ESD for initial-onset gastric cancer clini-
cally diagnosed as meeting ESD indication. Of them, 558 patients with pathologically non-
curative resection were excluded. As a result, the data for 1,560 patients with 1,592 lesions
resected curatively via ESD were analyzed. Of these, 1,478 lesions were differentiated cancers
and the rest were undifferentiated cancers. Table 1 shows the patient and lesion characteristics
according to the histologic differentiation of the tumor.
Elderly and male patients were more common in the differentiated cancer group compared
to the undifferentiated cancer group (differentiated cancer vs. undifferentiated cancer;>65
years, 44.3% vs. 24.8%, P< 0.001; male, 75.6% vs. 54.0%, P< 0.001). H. pylori infection was
identified in 831 (78.6%) and 89 (88.1%) patients in the differentiated and undifferentiated
cancer groups, respectively (P = 0.024). Patients with both atrophic gastritis and IM were also
more common in the differentiated cancer group than in the undifferentiated cancer group
(differentiated cancer vs. undifferentiated cancer; 62.1% vs. 38.1%, P< 0.001). Tumor size,
presence of ulcer, and depth of tumor invasion did differ between the two groups (P< 0.001,
P = 0.008, and P = 0.006, respectively), because all of the undifferentiated cancers that met the
expanded indication criteria were less than 2 cm in diameter, without ulcers or lymphovascular
invasion.
ESD for Undifferentiated Gastric Cancer
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Recurrence at the resection site (local recurrence)
Fig 1 shows the Kaplan-Meier plots for recurrence at the resection site after curative resection
according to the histologic differentiation of the primary lesion. The recurrence rate at the
resection site within 5 years was 3.6% and 6.2% in the differentiated and undifferentiated can-
cer groups, respectively. There was no significant difference between the two groups
(P = 0.307).
Recurrence at a site other than the primary resection area (synchronous
or metachronous tumor)
Fig 2 shows the Kaplan-Meier plots for recurrence at a gastric site other than the primary resec-
tion area (synchronous or metachronous tumor) after curative resection according to the histo-
logic differentiation of the primary lesion. The median follow-up duration was 16.8 (IQR, 6.5–
Table 1. Baseline patient and lesion characteristics.
Variable Primary lesion P-value Total
Differentiated cancer Undifferentiated cancer
Patients, n 1,447 113 1,560
Lesions, n 1,478 114 1,592
Age, n (%) <0.001
65 years 806 (55.7) 85 (75.2) 891 (57.1)
>65 years 641 (44.3) 28 (24.8) 669 (42.9)
Sex, n (%) <0.001
Male 1,094 (75.6) 61 (54.0) 1,155 (74.0)
Female 353 (24.4) 52 (46.0) 405 (26.0)
Helicobacter pylori infectiona,b 0.024
Absence 226 (21.4) 12 (11.9) 238 (20.6)
Presence 831 (78.6) 89 (88.1) 920 (79.4)
Atrophy and intestinal metaplasiac < 0.001
None 158 (10.9) 28 (24.8) 186 (11.9)
Atrophic gastritis without IM 391 (27.0) 42 (37.2) 433 (27.8)
Atrophic gastritis with IM 898 (62.1) 43 (38.1) 941 (60.3)
Location, n (%) 0.016
Upper third 104 (7.0) 9 (7.9) 113 (7.1)
Middle third 271 (18.3) 33 (28.9) 304 (19.1)
Lower third 1,103 (74.6) 72 (63.2) 1,175 (73.8)
Tumor size, n (%) <0.001
10 mm 703 (47.6) 67 (57.8) 770 (48.4)
10–20 mm 519 (35.1) 47 (41.2) 566 (35.6)
>20 mm 256 (17.3) 0 (0.0) 256 (16.1)
Presence of ulcer, n (%) 69 (4.7) 0 (0.0) 0.008 69 (4.3)
Depth of invasion, n (%) 0.006
Mucosa 1,385 (93.7) 114 (100.0) 1,499 (94.2)
Submucosa (<500 μm) 93 (6.3) 0 (0.0) 93 (5.8)
aH. pylori infection was tested by using a rapid urease test, a urea breath test, and histologic examination.
bData for H. pylori infection status were missing in 390 and 12 patients in the differentiated and undifferentiated cancer groups, respectively.
cAtrophy and intestinal metaplasia were assessed considering the endoscopic ﬁndings.
IM, intestinal metaplasia
doi:10.1371/journal.pone.0147874.t001
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34.8) months and 22.5 (IQR, 9.3–43.1) months in the differentiated and undifferentiated can-
cer groups, respectively (P = 0.014). Cumulative incidence was significantly higher in the differ-
entiated cancer group than in the undifferentiated cancer group (P = 0.008). Incidence of
recurrence was 4.8% and 1.2% per person-year in the differentiated and undifferentiated cancer
groups, respectively.
For the purpose of exploratory analysis, we compared recurrence rates at a site other than
the primary resection area according to the atrophic gastritis and IM status (S1 Fig). The
Fig 1. Kaplan-Meier plots for recurrence at the resection site after curative resection according to the
histologic differentiation of the primary lesion.
doi:10.1371/journal.pone.0147874.g001
Fig 2. Kaplan-Meier plots for recurrence at a gastric site other than the primary resection site after
curative resection according to the histologic differentiation of the primary lesion.
doi:10.1371/journal.pone.0147874.g002
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recurrence rate was significantly higher in the atrophic-gastritis-with-IM group than in the no-
atrophic-gastritis group (P = 0.006). However, the recurrence rate did not differ between the
atrophic-gastritis-without-IM group and atrophic-gastritis-with-IM or no-atrophic-gastritis
groups (P = 0.057 and P = 0.558, respectively).
The Cox proportional hazard model was used to adjust for possible confounding variables
(Table 2). Undifferentiated histology was significantly associated with a low risk of recurrence
at a site other than the primary resection area (hazard ratio [HR] [95% confidence interval
[CI]] = 0.287 [0.090–0.918]). Atrophic gastritis with IM was also an associated factor for recur-
rence at a site other than the primary resection area (with no atrophic gastritis as the reference
group: atrophic gastritis without IM, HR [95% CI] = 1.392 [0.653–2.968]; atrophic gastritis
with IM, HR [95% CI] = 2.220 [1.098–4.488]). Meanwhile, H. pylori infection was not associ-
ated with recurrence at a site other than the primary resection area (HR [95% CI] = 1.385
Table 2. Multivariable analysis for predicting recurrence at a gastric site other than the primary resec-
tion area.
Variable HR (95% CI) P-value
Age
65 years 1
>65 years 1.478 (1.043–2.095) 0.028
Sex, n (%)
Male 1.355 (0.864–2.125) 0.185
Female 1
Helicobacter pylori infectiona
Absence 1
Presence 1.385 (0.751–2.553) 0.297
Unknown 1.256 (0.646–2.441) 0.502
Atrophy or intestinal metaplasiab
None 1
Atrophic gastritis without IM 1.392 (0.653–2.969) 0.392
Atrophic gastritis with IM 2.220 (1.098–4.488) 0.026
Histology, n (%)
Differentiated 1
Undifferentiated 0.287 (0.090–0.918) 0.035
Location, n (%)
Upper third 1.016 (0.487–2.117) 0.967
Middle third 1.438 (0.944–2.191) 0.091
Lower third 1
Tumor size, n (%)
10 mm 1
10–20 mm 0.960 (0.662–1.393) 0.831
>20 mm 0.547 (0.301–0.997) 0.049
Presence of ulcer, n (%) 1.030 (0.450–2.355) 0.944
Depth of invasion, n (%)
Mucosa 1
Submucosa (<500 μm) 1.128 (0.566–2.250) 0.732
aH. pylori infection was tested by using a rapid urease test, a urea breath test, and histologic examination.
bAtrophy and intestinal metaplasia were assessed considering the endoscopic ﬁndings.
HR, hazard ratio; IM, intestinal metaplasia
doi:10.1371/journal.pone.0147874.t002
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[0.751–2.553]). In addition, old age and tumor size were associated factors for recurrence (old
age [>65 years], HR [95% CI] = 1.478 [1.043–2.095]; larger tumor size [>20 mm], HR [95%
CI] = 0.547 [0.450–2.355]).
Clinicopathological characteristics of recurrent tumor at a site other than
the primary resection area
The detailed clinicopathological characteristics of recurrent tumor at a gastric site other than
the primary resection site are shown in Table 3. During the follow-up period, 128 tumors were
identified as synchronous or metachronous tumors in the differentiated cancer group. About
half of the tumors were synchronous tumors and the others were metachronous tumors. In
contrast, only three synchronous tumors were identified in the undifferentiated cancer group.
There were no metachronous tumors in the undifferentiated cancer group. In the differentiated
cancer group, 6.3% of synchronous or metachronous tumors were identified as undifferenti-
ated cancers. In the undifferentiated cancer group, all three synchronous tumors developed as
adenoma or differentiated cancers.
Additional treatment for recurrent tumor at a site other than the primary
resection area
Additional treatments for recurrent tumor at a site other than the primary resection site are
described in Table 4. More additional treatments were required in the differentiated cancer
group than in the undifferentiated cancer group (7.8% vs. 1.8%, P = 0.018). Of the three syn-
chronous tumors in the undifferentiated cancer group, two (that were differentiated cancers)
were treated with endoscopic resection. The remaining tumor, an adenoma, was closely
observed.
Discussion
Metachronous tumor after surgery for gastric cancer has been considered to be of lesser impor-
tance compared to local recurrence or extra-gastric recurrence because recurrence in a remnant
stomach is rare [19–21]. In the era of ESD, however, metachronous tumors can no longer be
ignored. Because the ESD method preserves the whole stomach, the incidence of metachronous
tumors after ESD is higher than after surgery [20–22]. Risk of metachronous tumors is there-
fore a concern even if the primary lesion is treated successfully [21,23]. Almost all recurrent
tumors require additional treatments, and these will be a burden for patients who undergo
ESD [21].
In our study, we showed that the local disease control rate after curative resection via ESD
was excellent regardless of the degree of differentiation of the primary lesion. However, pat-
terns of recurrence at a gastric site other than the primary resection site did differ according to
the histologic differentiation of the primary lesion. The incidence of synchronous or metachro-
nous tumors after ESD for differentiated cancers remained steady over time, with an annual
incidence of 3.7%. At 5 years after ESD, synchronous or metachronous tumors developed in
about 19% of patients who had undergone curative resection via ESD. More metachronous
tumors would be expected to develop over a longer follow-up. In contrast to the results of ESD
for differentiated cancers, the incidence of synchronous or metachronous tumors after ESD for
undifferentiated cancers was relatively low. Within 5 years after ESD, only 3% of patients
showed recurrence at a site other than the primary resection site. Moreover, no metachronous
tumor was identified during the follow-up period. These findings suggest that ESD for undif-
ferentiated cancers may have better outcomes compared to that for differentiated cancers. If
ESD for Undifferentiated Gastric Cancer
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curative resection is achieved via ESD, the long-term oncologic outcome of undifferentiated
cancers may be superior to that of differentiated cancers in terms of the incidence of synchro-
nous or metachronous tumors after ESD.
The different patterns of recurrence after ESD may be due to the different pathogenesis of
gastric cancer according to the histologic differentiation. It has long been known that the devel-
opment of differentiated cancers is associated withH. pylori infection. Iseki et al. demonstrated
that differentiated adenocarcinomas were usually located in areas of mucosa infected with H.
pylori, while undifferentiated adenocarcinomas were frequently located in non-infected areas
[12]. Chronic gastritis due toH. pylori infection may induce intestinal-type gastric cancer via
atrophic gastritis, IM, and dysplasia [24–27]. Because atrophic gastritis and IM can spread
extensively due to persistent inflammation, additional dysplasia or gastric cancer may occur
Table 3. Clinicopathological characteristics of recurrent tumor at a gastric site other than the primary resection area according to the histologic
differentiation of the primary lesion.
Variable Primary lesion P-value
Differentiated cancer Undifferentiated cancer
Patient, n 128 3
Type of recurrence, n (%) 0.119
Synchronous tumor 62 (48.4) 3 (100.0)
Metachronous tumor 66 (51.6) 0 (0.0)
Histology, n (%) 0.386
Adenoma 81 (63.3) 1 (33.3)
Differentiated cancer 39 (30.5) 2 (66.7)
Undifferentiated cancer 8 (6.3) 0 (0.0)
Location, n (%) >0.999
Upper third 22 (17.2) 0 (0.0)
Middle third 31 (24.2) 1 (33.3)
Lower third 75 (58.6) 2 (66.7)
Tumor size, n (%) 0.675
10 mm 80 (62.5) 3 (100.0)
10–20 mm 35 (27.3) 0 (0.0)
>20 mm 13 (10.2) 0 (0.0)
doi:10.1371/journal.pone.0147874.t003
Table 4. Additional treatment for recurrent tumor at a gastric site other than the primary resection area.
Variable Primary lesion P-value
Differentiated cancer Undifferentiated cancer
Patient, n 1,447 113
Synchronous or metachronous tumor, n 128 3
Additional treatment for synchronous or metachronous tumor, n (%)a 113 (7.8) 2 (1.8) 0.018
Surgery 12 (0.8) 0 (0.0) >0.999
Endoscopic resection 89 (6.2) 2 (1.8) 0.056
APC ablation 11 (0.8) 0 (0.0) >0.999
Palliative chemotherapy 1 (0.1) 0 (0.0) >0.999
Observation for synchronous or metachronous lesion, n (%) 15 (1.0) 1 (0.9) >0.999
aThe proportion of variables was calculated from the number of enrolled patients.
APC, argon plasma coagulation
doi:10.1371/journal.pone.0147874.t004
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over time in patients with differentiated cancers. On the other hand, the rest of the gastric
mucosa may be relatively normal in patients with undifferentiated cancers. Therefore, the risk
of metachronous tumor may be relatively low in these patients. Our finding that atrophic gas-
tritis with IM was an associated risk factor for development of synchronous or metachronous
tumor also supports a hypothesis for pathogenesis of gastric cancer known as Correa’s
postulation.
In contrast to the results of atrophic gastritis and IM,H. pylori infection status did not have
any apparent influence on the development of synchronous or metachronous tumor after ESD
in our study. In addition, H. pylori infection was more common in the undifferentiated cancer
group than in the differentiated cancer group, while atrophic gastritis with IM was more com-
monly identified in the differentiated cancer group. These results may support that H. pylori
does not survive well in atrophic or IM mucosa [28]. Because patients with negative results for
H. pylori infection include bothH. pylori never-infected and past-infected patients, histologic
differentiation of primary EGC and atrophic gastritis with IM, rather than H. pylori infection
status, may be more useful for predicting development of synchronous or metachronous
tumor after ESD.
Another potential benefit of ESD for undifferentiated cancers is that a relatively longer gas-
trectomy-free survival may be expected for patients with undifferentiated cancers, because
undifferentiated cancers are more common in a younger population than are differentiated
cancers [29]. When considering the quality-adjusted life years of patients with gastric cancer
after ESD or surgery, ESD should be seriously considered as a first-line treatment in young
patients, especially in those with undifferentiated gastric cancers.
However, the low complete and curative resection rate is still a matter of concern in ESD for
undifferentiated cancers [1,7]. Despite various efforts to delineate the margin of undifferenti-
ated cancers, it is still difficult to discern the exact margin via endoscopy. Although magnifying
endoscopy with narrow-band imaging helps in the successful delineation of gastric cancers that
show an unclear margin, its usefulness for undifferentiated cancers has not been proven [8].
One attempt to overcome this limitation is an assessment of the margins by using confocal
laser endomicroscopy (CLE). CLE allows real-time, in vivo high-resolution and high-magnifi-
cation imaging of the gastrointestinal epithelium, which is comparable in accuracy to histopa-
thology [30]. Previous studies showed that CLE could provide an accurate diagnosis for gastric
cancer and adenoma [30,31]. Although there is currently a lack of evidence that CLE is useful
to delineate the cancer margin, a prospective study on delineation of the margin of EGC by
using CLE is ongoing (ClinicalTrials.gov Identifier: NCT02189226).
Although this study was the first to evaluate the incidence of recurrence at a gastric site
other than the primary resection site according to the histologic differentiation of the primary
lesion, the results should be interpreted cautiously because our study has several limitations.
The first limitation is the retrospective design of the study; however, all of the data were col-
lected prospectively for a future analysis of ESD performance. Accordingly, this limitation
introduces only a slight chance for bias. The second limitation is that lesion characteristics did
differ between the differentiated and undifferentiated groups because the expanded indication
criteria for ESD are different depending on the histologic differentiation of EGC. Differentiated
cancers that fulfill the expanded indication criteria for ESD can include larger tumors (>3 cm)
and tumors with ulcer or minute submucosal invasion (<500 μm), unlike undifferentiated can-
cers. Therefore, we cannot conclude for certain that undifferentiated cancers always have a low
incidence rate of synchronous or metachronous tumor compared to any other subgroups of
differentiated cancers. Even with the limitations of our study, we can conclude that undifferen-
tiated cancers that meet the expanded indication criteria have a lower incidence rate of syn-
chronous or metachronous tumors than differentiated cancers that fulfilled the expanded
ESD for Undifferentiated Gastric Cancer
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indication criteria. The exclusion of non-curatively resected lesion is the third limitation of the
study. Because patients underwent surgery when the primary lesion had been resected non-
curatively, we could not include them for analysis of metachronous tumor. Therefore, we can
say that the incidence rate of synchronous or metachronous tumors may be lower after ESD
for undifferentiated cancers than after ESD for differentiated cancers only if curative resection
has been achieved. The fourth limitation is a relatively short follow-up duration especially in
the differentiated cancer group. Although bias due to the censored data can be a concern for
interpreting survival data, however, it may be adjusted by the Kaplan-Meier method and the
Cox proportional hazard model. In addition, we think that relatively short follow-up duration
in the differentiated cancer group would not be a big problem, because the gap of incidence of
metachronous tumor between the differentiated and undifferentiated cancer groups may
expand if the follow-up duration in the differentiated cancer group increases. Finally, the fifth
limitation is that atrophic gastritis and IM, which are risk factors for gastric cancer, were evalu-
ated based on gross endoscopic findings only. Atrophic gastritis and IM can be assessed more
precisely by operative link on gastritis assessment (OLGA) and operative link on gastric IM
assessment (OLGIM) staging, respectively [32,33]. OLGA and OLGIM, however, require at
least five random biopsies. As these assessment methods are rather impractical, we decided to
use the assessment of atrophic gastritis and IM based on gross endoscopic findings.
Despite these limitations, our data may form the basis of a system to understand the benefit
of ESD for undifferentiated cancers. The incidence rate of recurrence at a gastric site other than
the primary resection site after curative resection was significantly lower after ESD for undiffer-
entiated cancers than after ESD for differentiated cancers. ESD for undifferentiated cancers can
be actively considered as a beneficial treatment when the lesion would be expected to be
resected curatively.
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S1 Fig. Kaplan-Meier plots for synchronous or metachronous tumor after curative resec-
tion according to the atrophic gastritis and intestinal metaplasia status. IM, intestinal meta-
plasia.
(TIF)
Author Contributions
Conceived and designed the experiments: CHP YCL. Performed the experiments: CHP EHK
JHK. Analyzed the data: CHP HC JCP. Contributed reagents/materials/analysis tools: JCP SKS
SKL. Wrote the paper: CHP YCL.
References
1. Park CH, Shin S, Park JC, Shin SK, Lee SK, Lee YC, et al. Long-term outcome of early gastric cancer
after endoscopic submucosal dissection: expanded indication is comparable to absolute indication. Dig
Liver Dis. 2013; 45: 651–656. doi: 10.1016/j.dld.2013.01.014 PMID: 23422031
2. Isomoto H, Shikuwa S, Yamaguchi N, Fukuda E, Ikeda K, Nishiyama H, et al. Endoscopic submucosal
dissection for early gastric cancer: a large-scale feasibility study. Gut. 2009; 58: 331–336. doi: 10.1136/
gut.2008.165381 PMID: 19001058
3. Yamaguchi N, Isomoto H, Fukuda E, Ikeda K, Nishiyama H, Akiyama M, et al. Clinical outcomes of
endoscopic submucosal dissection for early gastric cancer by indication criteria. Digestion. 2009; 80:
173–181. doi: 10.1159/000215388 PMID: 19776581
4. Lee H, YunWK, Min BH, Lee JH, Rhee PL, Kim KM, et al. A feasibility study on the expanded indication
for endoscopic submucosal dissection of early gastric cancer. Surg Endosc. 2011; 25: 1985–1993. doi:
10.1007/s00464-010-1499-7 PMID: 21136092
ESD for Undifferentiated Gastric Cancer
PLOS ONE | DOI:10.1371/journal.pone.0147874 January 25, 2016 11 / 13
5. Gotoda T. Endoscopic resection of early gastric cancer. Gastric Cancer. 2007; 10: 1–11. PMID:
17334711
6. Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al. Incidence of lymph node
metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gas-
tric Cancer. 2000; 3: 219–225. PMID: 11984739
7. Kim JH, Kim YH, Jung da H, Jeon HH, Lee YC, Lee H, et al. Follow-up outcomes of endoscopic resec-
tion for early gastric cancer with undifferentiated histology. Surg Endosc. 2014; 28: 2627–2633. doi: 10.
1007/s00464-014-3514-x PMID: 24718663
8. Nagahama T, Yao K, Maki S, Yasaka M, Takaki Y, Matsui T, et al. Usefulness of magnifying endoscopy
with narrow-band imaging for determining the horizontal extent of early gastric cancer when there is an
unclear margin by chromoendoscopy (with video). Gastrointestinal endoscopy. 2011; 74: 1259–1267.
doi: 10.1016/j.gie.2011.09.005 PMID: 22136775
9. Oka S, Tanaka S, Higashiyama M, Numata N, Sanomura Y, Yoshida S, et al. Clinical validity of the
expanded criteria for endoscopic resection of undifferentiated-type early gastric cancer based on long-
term outcomes. Surgical endoscopy. 2014; 28: 639–647. doi: 10.1007/s00464-013-3222-y PMID:
24114514
10. Shim CN, Lee SK. Endoscopic submucosal dissection for undifferentiated-type early gastric cancer: do
we have enough data to support this?World Journal of Gastroenterology. 2014; 20: 3938–3949. doi:
10.3748/wjg.v20.i14.3938 PMID: 24744583
11. Yamamoto Y, Fujisaki J, Omae M, Hirasawa T, Igarashi M. Helicobacter pylori-negative gastric cancer:
Characteristics and endoscopic findings. Dig Endosc. 2015.
12. Iseki K, Tatsuta M, Iishi H, Baba M, Ishiguro S. Helicobacter pylori infection in patients with early gastric
cancer by the endoscopic phenol red test. Gut. 1998; 42: 20–23. PMID: 9505880
13. Satoh K, Kimura K, Taniguchi Y, Yoshida Y, Kihira K, Takimoto T, et al. Distribution of inflammation and
atrophy in the stomach of Helicobacter pylori-positive and -negative patients with chronic gastritis. The
American journal of gastroenterology. 1996; 91: 963–969. PMID: 8633589
14. Ito S, Azuma T, Murakita H, Hirai M, Miyaji H, Ito Y, et al. Profile of Helicobacter pylori cytotoxin derived
from two areas of Japan with different prevalence of atrophic gastritis. Gut. 1996; 39: 800–806. PMID:
9038660
15. Liu Y, Uemura N, Xiao S, Tytgat GN, Kate FJ. Agreement between endoscopic and histological gastric
atrophy scores. Journal of gastroenterology. 2005; 40: 123–127. PMID: 15770394
16. Nagata N, Shimbo T, Akiyama J, Nakashima R, Kim HH, Yoshida T, et al. Predictability of gastric intes-
tinal metaplasia by mottled patchy erythema seen on endoscopy. Gastroenterology Research. 2011; 4:
203–209.
17. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, et al. The Vienna classifica-
tion of gastrointestinal epithelial neoplasia. Gut. 2000; 47: 251–255. PMID: 10896917
18. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14: 113–123. doi:
10.1007/s10120-011-0042-4 PMID: 21573742
19. Takeda J, Toyonaga A, Koufuji K, Kodama I, Aoyagi K, Yano S, et al. Early gastric cancer in the rem-
nant stomach. Hepato-gastroenterology. 1998; 45: 1907–1911. PMID: 9840174
20. Hosokawa O, Kaizaki Y, Watanabe K, Hattori M, Douden K, Hayashi H, et al. Endoscopic surveillance
for gastric remnant cancer after early cancer surgery. Endoscopy. 2002; 34: 469–473. PMID:
12048630
21. Park CH, Lee H, Kim DW, Chung H, Park JC, Shin SK, et al. Clinical safety of endoscopic submucosal
dissection compared with surgery in elderly patients with early gastric cancer: a propensity-matched
analysis. Gastrointest Endosc. 2014; 80: 599–609. doi: 10.1016/j.gie.2014.04.042 PMID: 24973177
22. Nakajima T, Oda I, Gotoda T, Hamanaka H, Eguchi T, Yokoi C, et al. Metachronous gastric cancers
after endoscopic resection: how effective is annual endoscopic surveillance? Gastric Cancer. 2006; 9:
93–98. PMID: 16767364
23. Park CH, Kim EH, Chung H, Park JC, Shin SK, Lee SK, et al. Role of computed tomography scan for
the primary surveillance of mucosal gastric cancer after complete resection by endoscopic submucosal
dissection. Surg Endosc. 2014; 28: 1307–1313. doi: 10.1007/s00464-013-3327-3 PMID: 24337190
24. Correa P. A humanmodel of gastric carcinogenesis. Cancer Res. 1988; 48: 3554–3560. PMID:
3288329
25. Vieth M, Stolte M. Elevated risk for gastric adenocarcinoma can be predicted from histomorphology.
World Journal of Gastroenterology. 2006; 12: 6109–6114. PMID: 17036380
26. AdamuMA,Weck MN, Gao L, Brenner H. Incidence of chronic atrophic gastritis: systematic review and
meta-analysis of follow-up studies. Eur J Epidemiol. 2010; 25: 439–448. doi: 10.1007/s10654-010-
9482-0 PMID: 20585973
ESD for Undifferentiated Gastric Cancer
PLOS ONE | DOI:10.1371/journal.pone.0147874 January 25, 2016 12 / 13
27. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic
atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Can-
cer. 2004; 109: 138–143. PMID: 14735480
28. Mizuno S, Miki I, Ishida T, Yoshida M, Onoyama M, Azuma T, et al. Prescreening of a high-risk group
for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig
Dis Sci. 2010; 55: 3132–3137. doi: 10.1007/s10620-010-1154-0 PMID: 20204698
29. Eguchi T, Takahashi Y, Yamagata M, Kasahara M, Fujii M. Gastric cancer in young patients. J Am Coll
Surg. 1999; 188: 22–26. PMID: 9915238
30. Bok GH, Jeon SR, Cho JY, LeeWC, Jin SY, Choi IH, et al. The accuracy of probe-based confocal endo-
microscopy versus conventional endoscopic biopsies for the diagnosis of superficial gastric neoplasia
(with videos). Gastrointestinal endoscopy. 2013; 77: 899–908. doi: 10.1016/j.gie.2013.01.018 PMID:
23473002
31. Jeon SR, ChoWY, Jin SY, Cheon YK, Choi SR, Cho JY. Optical biopsies by confocal endomicroscopy
prevent additive endoscopic biopsies before endoscopic submucosal dissection in gastric epithelial
neoplasias: a prospective, comparative study. Gastrointestinal endoscopy. 2011; 74: 772–780. doi: 10.
1016/j.gie.2011.05.005 PMID: 21802680
32. Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, et al. OLGA staging for gastritis: a
tutorial. Dig Liver Dis. 2008; 40: 650–658. doi: 10.1016/j.dld.2008.02.030 PMID: 18424244
33. Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis
with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis.
Gastrointestinal endoscopy. 2010; 71: 1150–1158. doi: 10.1016/j.gie.2009.12.029 PMID: 20381801
ESD for Undifferentiated Gastric Cancer
PLOS ONE | DOI:10.1371/journal.pone.0147874 January 25, 2016 13 / 13
